129 related articles for article (PubMed ID: 10221724)
1. The contribution of maternal serum markers in the early prenatal diagnosis of molar pregnancies.
Jauniaux E; Bersinger NA; Gulbis B; Meuris S
Hum Reprod; 1999 Mar; 14(3):842-6. PubMed ID: 10221724
[TBL] [Abstract][Full Text] [Related]
2. Obstetrical complications associated with abnormal maternal serum markers analytes.
Gagnon A; Wilson RD;
J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
[TBL] [Abstract][Full Text] [Related]
3. Early ultrasound diagnosis and follow-up of molar pregnancies.
Jauniaux E; Nicolaides KH
Ultrasound Obstet Gynecol; 1997 Jan; 9(1):17-21. PubMed ID: 9060124
[TBL] [Abstract][Full Text] [Related]
4. Triploid partial molar pregnancy detected through maternal serum alpha-fetoprotein and HCG screening.
Harper MA; Ruiz C; Pettenati MJ; Rao PN
Obstet Gynecol; 1994 May; 83(5 Pt 2):844-6. PubMed ID: 7512706
[TBL] [Abstract][Full Text] [Related]
5. 'Dual positivity' for neural tube defects and down syndrome at maternal serum screening: gestational outcome.
Zanini R; Tarantini M; Cerri V; Jacobello C; Bellotti D; Lancetti S; Scalchi S; Groli C; Bianchi UA
Fetal Diagn Ther; 1998; 13(2):106-10. PubMed ID: 9650657
[TBL] [Abstract][Full Text] [Related]
6. Maternal serum hyperglycosylated human chorionic gonadotrophin (HhCG) in the first trimester of pregnancies affected by Down syndrome, using a sialic acid-specific lectin immunoassay.
Spencer K; Talbot JA; Abushoufa RA
Prenat Diagn; 2002 Aug; 22(8):656-62. PubMed ID: 12210572
[TBL] [Abstract][Full Text] [Related]
7. Co-variables in first trimester maternal serum screening.
de Graaf IM; Cuckle HS; Pajkrt E; Leschot NJ; Bleker OP; van Lith JM
Prenat Diagn; 2000 Mar; 20(3):186-9. PubMed ID: 10719318
[TBL] [Abstract][Full Text] [Related]
8. Combined screening for open spina bifida at 11-13 weeks using fetal biparietal diameter and maternal serum markers.
Bernard JP; Cuckle HS; Bernard MA; Brochet C; Salomon LJ; Ville Y
Am J Obstet Gynecol; 2013 Sep; 209(3):223.e1-5. PubMed ID: 23673229
[TBL] [Abstract][Full Text] [Related]
9. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
[TBL] [Abstract][Full Text] [Related]
10. [Early diagnosis of molar pregnancy by measuring AFP and HCG in serum (author's transl)].
Dericks-Tan JS; Taubert HD
Geburtshilfe Frauenheilkd; 1980 Oct; 40(10):933-5. PubMed ID: 6160078
[TBL] [Abstract][Full Text] [Related]
11. Clinical management and diagnostic possibilities in hydatidiform mole with coexistent fetus.
Vejerslev LO
Obstet Gynecol Surv; 1991 Sep; 46(9):577-88. PubMed ID: 1720883
[TBL] [Abstract][Full Text] [Related]
12. Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30-34 weeks.
Bakalis S; Gallo DM; Mendez O; Poon LC; Nicolaides KH
Ultrasound Obstet Gynecol; 2015 Aug; 46(2):208-15. PubMed ID: 25826797
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of alpha-fetoprotein and pregnancy specific beta1 glycoprotein in pregnancies without an embryo.
Bennett MJ; Grudzinskas JG; Gordon YB; Turnbull AC
Br J Obstet Gynaecol; 1978 May; 85(5):348-50. PubMed ID: 77162
[TBL] [Abstract][Full Text] [Related]
14. Term delivery of a complete hydatidiform mole with a coexisting living fetus followed by successful treatment of maternal metastatic gestational trophoblastic disease.
Peng HH; Huang KG; Chueh HY; Adlan AS; Chang SD; Lee CL
Taiwan J Obstet Gynecol; 2014 Sep; 53(3):397-400. PubMed ID: 25286799
[TBL] [Abstract][Full Text] [Related]
15. Prenatal screening for fetal aneuploidy in singleton pregnancies.
Chitayat D; Langlois S; Douglas Wilson R; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
[TBL] [Abstract][Full Text] [Related]
16. [Prenatal diagnosis of molar pathologies coexisting with a fetus. Review of the recent literature and a case report].
Jauniaux E; de Lannoy E; Moscoso G; Campbell S
J Gynecol Obstet Biol Reprod (Paris); 1990; 19(8):941-6. PubMed ID: 1707073
[TBL] [Abstract][Full Text] [Related]
17. Clinical presentation and management of molar pregnancy.
Sasaki S
Best Pract Res Clin Obstet Gynaecol; 2003 Dec; 17(6):885-92. PubMed ID: 14614887
[TBL] [Abstract][Full Text] [Related]
18. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
19. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down's syndrome.
Spencer K; Crossley JA; Aitken DA; Nix AB; Dunstan FD; Williams K
Ann Clin Biochem; 2003 May; 40(Pt 3):219-31. PubMed ID: 12803832
[TBL] [Abstract][Full Text] [Related]
20. Maternal serum testing for alpha-fetoprotein and human chorionic gonadotropin in high-risk pregnancies.
Jauniaux E; Gulbis B; Tunkel S; Ramsay B; Campbell S; Meuris S
Prenat Diagn; 1996 Dec; 16(12):1129-35. PubMed ID: 8994249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
